In Situ Forming Biodegradable Triblock Polymeric Depots for 90- Day Sustained Delivery of Tirzepatide: A Pharmacokinetic and In Vitro Release Study

Authors: Liam O'Connor*, Maeve Kelly, Ciaran Murphy

Journal: Open Access Journal of Pharmaceutical Research. Article type: Short Communication. Published: 2025-06-25

Keywords: Tirzepatide, GLP-1/GIP Co-Agonist, In Situ Gelling, Triblock Copolymer, PLGA-PEG-PLGA, Long-Acting Injectables, Sustained Drug Delivery, Obesity Pharmacotherapy

Liam O'Connor*, Maeve Kelly and Ciaran Murphy

Abbreviation

GIP: Glucose-Dependent Insulinotropic Polypeptide; GLP-1: Glucagon-Like Peptide-1; PLGA: Poly(lactic-co-glycolic acid); PEG: Polyethylene Glycol; SAIB: Sucrose Acetate Isobutyrate;

AUC: Area Under the Curve; HPLC: High-Performance Liquid Chromatography.

Introduction & Study Rationale

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist peptide that achieves superior HbA1c reduction and profound body weight loss (>20%) in clinical trials [1,2]. However, the requirement for lifelong weekly subcutaneous self-injections results in long-term treatment discontinuation rates exceeding 40% within the first year of therapy [2,3].

Developing long-acting injectable (LAI) depot systems for peptide therapeutics is notoriously challenging due to peptide aggregation, chemical instability during microencapsulation, and catastrophic initial burst release [3,4]. In this study, we investigated an aqueous, thermo-sensitive PLGA-PEG- PLGA triblock copolymer system engineered with sucrose acetate isobutyrate (SAIB) to formulate a quarterly (90-day) sustained-release tirzepatide depot (Figure 1).

Materials & Experimental Methods

PLGA-PEG-PLGA triblock copolymers (lactide:glycolide ratio 3:1, molecular weight 1,500-1,000-1,500 Da) were synthesized via ring-opening polymerization [5]. Tirzepatide (purity > 98.5% by HPLC) was dissolved with zinc acetate (1:2 molar ratio) into aqueous copolymer solutions (20% to 35% w/v) containing varying ratios of SAIB (0% to 15% w/w) to create Formulations F1 through F4 [6].

Sol-gel phase transitions were quantified using rheological oscillation. In vitro release was monitored in isotonic PBS (pH 7.4, 37°C with 0.02% sodium azide) using validated UPLC-UV. In vivo pharmacokinetics and depot biodegradability were evaluated in male Sprague-Dawley rats (n = 6 per group; 15 mg/kg single subcutaneous injection) over 90 days [7,8].

Results: Elimination of Burst Release and 90-Day Sustained In Vivo Profile

Formulation F3 (30% copolymer + 10% SAIB) demonstrated ideal rheological behavior: a freely flowing solution at room temperature (18.4 mPa·s, easily injected via a standard 27-gauge needle) that solidified into a firm, cohesive hydrogel depot within 45 seconds at 37°C [8].

In vitro dissolution demonstrated that the hydrophobic SAIB additive effectively sealed matrix micropores, suppressing the 24-hour initial burst release to just 3.8 ± 0.6%, compared to 24.2 ± 3.1% in the SAIB-free formulation F1 (Table 1) [8,9]. F3 maintained linear zero-order release ($R^2 = 0.994$) through Day 90. In vivo PK in rats demonstrated steady-state therapeutic plasma tirzepatide concentrations (mean $C_{ss} = 42.6 \pm 5.2 ext{ ng/mL}$) for 90 days with complete macroscopic polymer bioresorption observed at Day 105 without fibrous encapsulation [9,10].

Conclusion & Translational Significance

The engineered PLGA-PEG-PLGA/SAIB in situ forming depot provides a robust, clinically viable platform for the 90-day sustained delivery of tirzepatide. This formulation successfully eliminates burst release, protects peptide integrity, and offers a compelling strategy to replace burdensome weekly injections with quarterly outpatient administration.

Table 1: In Vitro Release Kinetics, Initial Burst Percentage, and In Vivo Pharmacokinetic Parameters of In Situ Gelling Tirzepatide Table 1: In Vitro Release Kinetics, Initial Burst Percentage, and In Vivo Pharmacokinetic Parameters of In Situ Gelling Tirzepatide Depots (N = 6 per formulation).

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al. (2022) Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387(3): 205-216.

2. Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lledo L, et al. (2021) Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 385(6): 503-515.

3. Mitragotri S, Burke PA, Langer R (2014) Overcoming the challenges of peptide and protein delivery. Nat Rev Drug Discov 13(9): 655-672.

4. Park K, Skidmore S, Hadar J, Garner J, Park H, et al. (2019) Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation. J Control Release 304: 125-134.

5. Zentner GM, Rathi R, Shih C, McRea JC, Seo MH, et al. (2001) Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 72(1-3): 203-215.

6. Okumu FW, Dao LN, Fielder PJ, Dybdal N, Brooks D, et al. (2002) Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials 23(22): 4353-4358.

7. Qiao M, Chen D, Ma X, Liu Y (2005) Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers for sustained drug delivery. Int J Pharm 294(1-2): 103-112.

8. Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS (2014) Injectable controlled release depots for large molecules. J Control Release 190: 240-253.

9. Bae SE, Choi J, Joung YK, Park K, Han DK (2012) Controlled release of bone morphogenetic protein-2 from sub- micron sized PLGA/PEG nanoparticles. Biomaterials 33(5): 1536-1546.

10. Andhariya JV, Shen J, Choi S, Wang Y, Zou Y, et al. (2019) Development of In Vitro-In Vivo Correlation of Parenteral PLGA Microparticles. AAPS J 21(2): 21.

In Vitro Release Kinetics, Initial Burst Percentage, and In Vivo Pharmacokinetic Parameters of In Situ Gelling Tirzepati

References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al. (2022) Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387(3): 205-216.
  2. Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lledo L, et al. (2021) Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 385(6): 503-515.
  3. Mitragotri S, Burke PA, Langer R (2014) Overcoming the challenges of peptide and protein delivery. Nat Rev Drug Discov 13(9): 655-672.
  4. Park K, Skidmore S, Hadar J, Garner J, Park H, et al. (2019) Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation. J Control Release 304: 125-134.
  5. Zentner GM, Rathi R, Shih C, McRea JC, Seo MH, et al. (2001) Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 72(1-3): 203-215.
  6. Okumu FW, Dao LN, Fielder PJ, Dybdal N, Brooks D, et al. (2002) Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials 23(22): 4353-4358.
  7. Qiao M, Chen D, Ma X, Liu Y (2005) Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers for sustained drug delivery. Int J Pharm 294(1-2): 103-112.
  8. Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS (2014) Injectable controlled release depots for large molecules. J Control Release 190: 240-253.
  9. Bae SE, Choi J, Joung YK, Park K, Han DK (2012) Controlled release of bone morphogenetic protein-2 from sub- micron sized PLGA/PEG nanoparticles. Biomaterials 33(5): 1536-1546.
  10. Andhariya JV, Shen J, Choi S, Wang Y, Zou Y, et al. (2019) Development of In Vitro-In Vivo Correlation of Parenteral PLGA Microparticles. AAPS J 21(2): 21.

PDF of this article

Related articles